ResearcherSichuan UniversityNo recent work listed

Dan Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2180-0464; OpenAlex author ID A5103098573. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper

Papers 2

Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an o… Co-author DOI 10.21203/rs.3.rs-3677396/v1 ↗
The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanced Pancreatic Ductal Adenocarcinoma Last author DOI 10.21203/rs.3.rs-60530/v1 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chengjian Zhao · 1 shared paper, 2023 · strength 0.14
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗
Wanrui Lv · 1 shared paper, 2023 · strength 0.14
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗
Zixing Huang · 1 shared paper, 2023 · strength 0.14
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗
Junjie Xiong · 1 shared paper, 2023 · strength 0.14
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗
Ke Cheng · 1 shared paper, 2023 · strength 0.14
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗
Bole Tian · 1 shared paper, 2023 · strength 0.14
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗
Rui Wang · 1 shared paper, 2023 · strength 0.14
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗
Li Mao · 1 shared paper, 2020 · strength 0.11
- Paper The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanc… DOI 10.21203/rs.3.rs-60530/v1 ↗
Ang Li · 1 shared paper, 2020 · strength 0.11
- Paper The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanc… DOI 10.21203/rs.3.rs-60530/v1 ↗
Lin Shui · 1 shared paper, 2020 · strength 0.11
- Paper The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanc… DOI 10.21203/rs.3.rs-60530/v1 ↗
Bole Tian · 1 shared paper, 2020 · strength 0.11
- Paper The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanc… DOI 10.21203/rs.3.rs-60530/v1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.